July 30, 2008 - Clinical trial data presented to two scientific workshops at the International Conference on Alzheimer’s Disease and Related Disorders (ICAD 2008) validate the therapeutic potential of addressing the “tangles” component of the classic Alzheimer’s “plaques and tangles” pathology. The data from a clinical trial evaluating drug candidate AL-108 in 144 patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer’s disease, demonstrated that specific memory function improved in patients who were given AL-108 over 12 weeks...
...AL-108 is being developed by Allon Therapeutics (TSX: NPC), a Canadian biotechnology company located in Vancouver. The drug was discovered by Prof. Gozes of the Sackler Faculty of Medicine at Tel Aviv University. Prof. Collaborative research led by Prof. Gozes has been supported by Tel Aviv University and the U.S. National Institutes of Health... Allon Therapeutics' Press Release -
